CLINICAL_TRIALS
trial_result
· 2017-06-07
Clinical Trial Update: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia [Phase 3]
Summary
Phase 3 trial evaluating NewGam (intravenous immunoglobulin 10%) for primary immune thrombocytopenia; efficacy and safety results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Octapharma | Conditions: Primary Thrombocytopenia | Phase 3 | Status: COMPLETED | Results posted: 2017-06-07